Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
Vitamin D associates with the plasma concentration of the endogenous inhibitor of the nitric oxide system asymmetric dimethyl arginine (ADMA) and cross-sectional studies in CKD patients treated with the vitamin D receptor activator paricalcitol show that plasma ADMA is substantially less than in those not receiving this drug.
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Double-blind reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
In the frame of a randomized, double-blind, placebo controlled trial, the Paracalcitol and ENdothelial fuNction in chronic kidneY disease (PENNY), we investigated whether vitamin D receptor activation by paricalcitol (2 μg/day x 12 weeks) affects the plasma concentration of ADMA and symmetric dimethyl arginine (SDMA) in 88 patients with stage 3 to 4 CKD.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Vitamin D and methylarginines in chronic kidney disease (CKD)
Study design awaiting verification · PLoS ONE · 2017
Original publication title
Vitamin D and methylarginines in chronic kidney disease (CKD)
© 2017 Torino et al
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Vitamin D associates with the plasma concentration of the endogenous inhibitor of the nitric oxide system asymmetric dimethyl arginine (ADMA) and cross-sectional studies in CKD patients treated with the vitamin D receptor activator paricalcitol show that plasma ADMA is substantially less than in those not receiving this drug.
Source: BackgroundAbstract: What methods does the paper describe?
In the frame of a randomized, double-blind, placebo controlled trial, the Paracalcitol and ENdothelial fuNction in chronic kidneY disease (PENNY), we investigated whether vitamin D receptor activation by paricalcitol (2 μg/day x 12 weeks) affects the plasma concentration of ADMA and symmetric dimethyl arginine (SDMA) in 88 patients with stage 3 to 4 CKD.
Source: MethodsAbstract: Results
Paricalcitol produced the expected small rise in serum calcium and phosphate and a marked PTH suppression. However, ADMA [Paricalcitol: baseline 0.75 μMol/L (95%CI: 0.70 to 0.81), 12 week 0.72 μMol/L (95%CI: 0.66 to 0.78); Placebo: baseline 0.75 μMol/L (95%CI: 0.70 to 0.90) 12 weeks 0.70 μMol/L (95%CI: 0.66 to 0.74)] and SDMA [Paricalcitol: baseline 0.91 μMol/L (95%CI: 0.82 to 1.00), 12 week 0.94 μMol/L (95%CI: 0.82 to 0.1.06); Placebo: baseline 0.91 μMol/L (95%CI: 0.82 to 1.06) 12 weeks 0.99 μMol/L (95%CI: 0.88 to 1.10)] remained unchanged during the trial and 2 weeks after stopping these treatments.
Source: ResultsAbstract: Conclusions
Paricalcitol does not modify plasma ADMA and SDMA in patients with stage 3 to 4 CKD. The apparent beneficial effects of paricalcitol on ADMA registered in cross-sectional studies is likely attributable to confounding by indication rather than to a true effect of this drug on ADMA metabolism.
Source: ConclusionsAuthors’ abstract
Background
Vitamin D associates with the plasma concentration of the endogenous inhibitor of the nitric oxide system asymmetric dimethyl arginine (ADMA) and cross-sectional studies in CKD patients treated with the vitamin D receptor activator paricalcitol show that plasma ADMA is substantially less than in those not receiving this drug.
Methods
In the frame of a randomized, double-blind, placebo controlled trial, the Paracalcitol and ENdothelial fuNction in chronic kidneY disease (PENNY), we investigated whether vitamin D receptor activation by paricalcitol (2 μg/day x 12 weeks) affects the plasma concentration of ADMA and symmetric dimethyl arginine (SDMA) in 88 patients with stage 3 to 4 CKD.
Results
Paricalcitol produced the expected small rise in serum calcium and phosphate and a marked PTH suppression. However, ADMA [Paricalcitol: baseline 0.75 μMol/L (95%CI: 0.70 to 0.81), 12 week 0.72 μMol/L (95%CI: 0.66 to 0.78); Placebo: baseline 0.75 μMol/L (95%CI: 0.70 to 0.90) 12 weeks 0.70 μMol/L (95%CI: 0.66 to 0.74)] and SDMA [Paricalcitol: baseline 0.91 μMol/L (95%CI: 0.82 to 1.00), 12 week 0.94 μMol/L (95%CI: 0.82 to 0.1.06); Placebo: baseline 0.91 μMol/L (95%CI: 0.82 to 1.06) 12 weeks 0.99 μMol/L (95%CI: 0.88 to 1.10)] remained unchanged during the trial and 2 weeks after stopping these treatments.
Conclusions
Paricalcitol does not modify plasma ADMA and SDMA in patients with stage 3 to 4 CKD. The apparent beneficial effects of paricalcitol on ADMA registered in cross-sectional studies is likely attributable to confounding by indication rather than to a true effect of this drug on ADMA metabolism.
Publication and source details
Original title: Vitamin D and methylarginines in chronic kidney disease (CKD)
Claudia Torino; Patrizia Pizzini; Sebastiano Cutrupi; Rocco Tripepi; Giovanni Tripepi; Francesca Mallamaci; Carmine Zoccali
PLoS ONE · 2017
Competing Interests: CZ received honoraria for lectures from AbbVie, Amgen, Genzyme, Roche, Shire. FM received honoraria for lectures by Amgen and Shire and GT by AbbVie. The other authors report no conflict of interest.This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T22:26:47.175164+00:00
DOI: 10.1371/journal.pone.0185449 · PMC5627906